A double-blind placebo controlled trial of ginkgo biloba added to risperidone in patients with autistic disorders

Child Psychiatry and Human Development

Volumn 43, Issue 5, 2012, Pages 674-682

  Hasanzadeh, Elmira ^a   Mohammadi, Mohammad Reza ^a   Ghanizadeh, Ahmad ^b   Rezazadeh, Shams Ali ^c   Tabrizi, Mina ^d   Rezaei, Farzin ^e   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Institute of Medicinal Plants Iran   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autism; Clinical trial; Ginkgo biloba; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; PLANT EXTRACT; RISPERIDONE;

ARTICLE; AUTISM; CHILD; CHILD BEHAVIOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GINKGO BILOBA; HUMAN; IRAN; MALE; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; PRESCHOOL CHILD; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; CHILD; CHILD BEHAVIOR; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GINKGO BILOBA; HUMANS; IRAN; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; TREATMENT OUTCOME;

EID: 84866257945     PISSN: 0009398X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10578-012-0292-3     Document Type: Article

References (25)

1. American Psychiatric Association (2000) American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders DSM IV-TR, 4th edn (Text Revision). American Psychiatric Press, Washington DC
2. Autism and Developmental Disabilities Monitoring Network Surveillance Year (2006) Principal investigators; centers for disease control and prevention (CDC) (2009) Prevalence of autism spectrum disorders: autism and developmental disabilities monitoring network, United States, 2006. MMWR Surveill Summ 58:1-20
3. Steyaert JG, De la Marche W (2008) What's new in autism? Eur J Pediatr 167:1091-1101
4. Bölte S, Poustka F (2003) Genetic, environmental and immunologic factors in the etiology of autism spectrum disorders. Neuroembryology 2:175-179
5. Bent S, Hendren RL (2010) Improving the prediction of response to therapy in autism. Neurotherapeutics 7:232-240
6. Ratajczak HV (2011) Theoretical aspects of autism: causes-a review. J Immunotoxicol 8:68-79
7. Mohammadi MR, Akhondzadeh S (2007) Autism spectrum disorders: etiology and pharmacotherapy. Current Drug Therapy 2:97-103
8. Leskovec TJ, Rowles BM, Findling RL (2008) Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 16:97-112
9. West L, Waldrop J, Brunssen S (2009) Pharmacologic treatment for the core deceits and associated symptoms of autism in children. J Pediatr Health Care 23:75-89
10. Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years. Ped Health 4:375-381
11. Levy SE, Hyman SL (2008) Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatry Clin N Am 17:803-820
12. Akins RS, Angkustsiri K, Hansen RL (2010) Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families. Neurotherapeutics 7:307-319
13. Hanson E, Kalish LA, Bunce E, Curtis C, McDaniel S, Ware J, Petry J (2007) Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 37:628-636
14. Beaubrun G, Gray GE (2000) A review of herbal medicines for psychiatric disorders. Psychiatry Serv 51:1130-1134
15. Maclennan KM, Darlington CL, Smith PF (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 67:235-257
16. Niederhofer H (2009) First preliminary results of an observation of Ginkgo biloba treating patients with autistic disorder. Phytother Res 23:1645-1646
17. DeFeudis FV, Drieu K (2000) Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1:25-58
18. Akhondzadeh S (1999) Hippocampal synaptic plasticity and cognition. J Clin Pharm Ther 24:241-248
19. Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, Ghelichnia HA (2008) A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 39:237-245
20. Itil TM, Eralp E, Ahmed I, Kunitz A, Itil KZ (1998) The pharmacological effects of Ginkgo Biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull 34:391-397
21. Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491
22. Lord C, Rutter M, Le Couteur A (1994) Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685
23. Akhondzadeh S, Erfani S, Mohammadi MR, Tehrani-Doost M, Amini H, Gudarzi SS, Yasamy MT (2004) Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther 29:145-150
24. Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, Ghanizadeh A, Raznahan M, Mohebbi-Rasa S, Rezazadeh SA, Forghani S (2010) Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 34:32-36
25. Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, Akhondzadeh S (2010) Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 34:1269-1272